# Restless Legs Syndrome: Study Shows Symptom Improvement with THC and CBD Combination > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/restless-legs-syndrome-study-shows-symptom-improvement-with-thc-and-cbd-combination/ > **Published:** 2026-07-29T17:16:33-04:00 | **Last Modified / Clinically Audited:** 2026-09-09T10:02:24-04:00 > **Clinical Summary:** Clinical commentary on cannabis RLS symptom relief study. Evidence summary, safety considerations, and guidance for clinicians. --- ✦ New CED Clinical Relevance #72 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. SleepPainNeurologyResearchCBDTHCSafety Why This Matters Clinicians treating restless legs syndrome patients who have failed conventional therapies now have evidence supporting a cannabinoid option, as the study demonstrates THC/CBD combinations reduce symptoms and improve sleep quality. This finding is particularly relevant for patients with RLS-related insomnia or pain who experience adverse effects from standard medications like dopamine agonists or benzodiazepines. However, clinicians must consider local cannabis legality, [drug interactions](https://cedclinic.com/cannabis-liver-interactions-study-insights/), and the small study sample size when counseling patients about this emerging treatment option. Clinical Summary This Brazilian [clinical study](https://cedclinic.com/cannabis-hyperemesis-syndrome-psychiatric-risk/) evaluated a combined THC and CBD cannabis extract in patients with restless legs syndrome (RLS), a condition characterized by uncomfortable sensations in the legs and sleep disruption that significantly impacts [quality of life](https://cedclinic.com/cannabis-policy-enforcement-february-26-2026/). The research demonstrated that patients receiving the cannabis combination experienced meaningful reductions in pain, improvements in sleep quality, and enhanced physical functioning compared to baseline or control conditions. These findings suggest that [cannabinoid therapy](https://cedclinic.com/unknown-cannabinoid-receptor-brain-damage-relief/) may address multiple symptom domains in RLS simultaneously, potentially offering an alternative for patients who do not respond adequately to standard medications like dopamine agonists or who experience intolerable [side effects](https://cedclinic.com/cannabis-intoxication-memory-disruption/). However, clinicians should note that this represents early-stage evidence from a single study and that RLS management remains primarily guided by established pharmacological and non-pharmacological approaches. For patients considering or using cannabis for RLS symptoms, a structured discussion about this emerging evidence, [drug interactions](https://cedclinic.com/cannabis-liver-interactions-study-insights/) with existing RLS medications, and individual tolerance would be warranted before incorporation into treatment plans. Dr. Caplan’s Take “We’re seeing some encouraging early signals in this Brazilian cohort around THC and CBD for restless legs syndrome, particularly with sleep and discomfort metrics, but we need to be careful here—27 patients is a modest sample size, and we’ll want to see these results replicated in larger, controlled trials before I’d feel confident recommending cannabinoids as a primary treatment approach in my own practice.” Clinical Perspective 💤 While this small Brazilian study suggests potential symptomatic benefit of THC/CBD combination for restless legs syndrome, clinicians should note several important limitations before considering cannabis as a treatment option. The study’s modest sample size, lack of comparison group, and absence of standardized RLS severity scales limit the generalizability of findings, and we lack information on dosing consistency, patient selection criteria, and whether improvements represent placebo effects or natural disease fluctuation. Additionally, THC use carries risks of cognitive effects, dependence, and [drug interactions](https://cedclinic.com/cannabis-liver-interactions-study-insights/) that may be particularly relevant for RLS patients who often have comorbid sleep disorders or neurological conditions. Until larger, controlled trials establish efficacy and optimal dosing, cannabis cannot yet replace evidence-based RLS treatments like dopamine agonists or gabapentinoids, though clinicians might cautiously explore cannabis as an adjunctive option in carefully selected patients who have failed conventional therapies and can tolerate 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/) Have thoughts on this? Share it: [X Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20Restless%20Legs%20Syndrome%3A%20Study%20Shows%20Symptom%20Improvement%20with%20THC%20and%20CBD%20Combination%20%40drcaplan&url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D71685)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D71685)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20Restless%20Legs%20Syndrome%3A%20Study%20Shows%20Symptom%20Improvement%20with%20THC%20and%20CBD%20Combination%20via%20%40drcaplan.bsky.social%20https%3A%2F%2Fcedclinic.com%2F%3Fp%3D71685)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan)[📝 Read more on Substack](https://doctorapprovedcannabis.substack.com/)[🔔 Subscribe via RSS](https://cedclinic.com/feed/) Related Articles - [Evidence for pro-cognitive benefits of cannabinoids in people with bipolar disorder](https://cedclinic.com/evidence-for-pro-cognitive-benefits-of-cannabinoids-in-people-with-bipolar-disorder/) - [Oral Cannabis Spray Improves Restless Legs Syndrome](https://cedclinic.com/oral-cannabis-spray-improves-restless-legs-syndrome/) - [Using cannabis for sleep isn’t harmless – it can trap people in a cycle of dependency](https://cedclinic.com/using-cannabis-for-sleep-isnt-harmless-it-can-trap-people-in-a-cycle-of-dependency/) 📰 Source: [https://sechat.com.br/en/noticia/restless-legs-syndrome-study-shows-symptom-improvement-with-thc-and-cbd-combination](https://sechat.com.br/en/noticia/restless-legs-syndrome-study-shows-symptom-improvement-with-thc-and-cbd-combination) Further Reading CED Clinic Blog[Why Cannabis Works](https://cedclinic.com/why-cannabis-works/) Evidence Watch[Cannabis and Heart Health](https://cedclinic.com/cannabis-cardiovascular-health-study/) CED Clinic Blog[Cannabis for Sleep](https://cedclinic.com/cannabis-for-sleep/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).